<DOC>
	<DOCNO>NCT02528266</DOCNO>
	<brief_summary>This study conduct clinically assess safety performance Polyganics nerve cap device treatment symptomatic neuroma . There sufficient clinical experience regard safety commercially available nerve guide , NEUROLAC® . This new nerve cap device identical material manufacturing . The exception design , NEUROLAC® two open end , nerve cap device one close ( seal ) end . This study conduct obtain data clinical performance cap device 's ability isolate nerve end , result reduction pain experience symptomatic neuroma prevention reoccurrence symptomatic neuroma .</brief_summary>
	<brief_title>Surgical Treatment Symptomatic Neuroma</brief_title>
	<detailed_description />
	<mesh_term>Neuroma</mesh_term>
	<criteria>Subjects eligible accord follow criterion : 1 . Subjects able provide write informed consent prior participate clinical investigation . 2 . Subjects &gt; 18 year year old . 3 . Subjects diagnosis symptomatic primary secondary endneuroma . 4 . Symptomatic neuroma locate upper limb metacarpophalangeal ( MCP ) joint shoulder . 5 . Symptomatic neuroma confirm pain relief follow 10min ±2min nerve block Xylocaine ( Lidocaine ) Pain relief define reduction VAS questionnaire score . 6 . Subjects history pain area endneuroma least 6months . 7 . Subjects positive Tinel 's sign . Subjects meet follow criterion exclude participation : 1 . Inability comply clinical investigation followup clinical investigation requirement . 2 . Subjects pregnant intend become pregnant duration clinical investigation subject use appropriate birth control . 3 . Subjects historical radiotherapy area endneuroma . 4 . Symptomatic neuroma locate proximally shoulder distally MCP joint . 5 . Subjects willing follow postsurgery protocol ( e.g . avoid pressure implant zone ) . 6 . Subjects involve another pain study . 7 . Subjects know allergy anesthetic agent bioresorbable copolyester Poly ( 68/32 [ 15/85 D/L ] LactideԐCaprolactone ) ( PLCL ) . 8 . Subjects symptomatic neuroma underwent surgical treatment pain management two occasion . 9 . Insufficient soft tissue endneuroma site cover investigational device . 10 . Immunosuppressed patient , patient plan immunosuppressive therapy within 12month follow study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>